TR199800912T2 - T�m�r a��s� ve a��n�n haz�rlanmas� i�in usul. - Google Patents

T�m�r a��s� ve a��n�n haz�rlanmas� i�in usul.

Info

Publication number
TR199800912T2
TR199800912T2 TR1998/00912T TR9800912T TR199800912T2 TR 199800912 T2 TR199800912 T2 TR 199800912T2 TR 1998/00912 T TR1998/00912 T TR 1998/00912T TR 9800912 T TR9800912 T TR 9800912T TR 199800912 T2 TR199800912 T2 TR 199800912T2
Authority
TR
Turkey
Prior art keywords
tumor
croup
crotch
procedure
preparation
Prior art date
Application number
TR1998/00912T
Other languages
English (en)
Turkish (tr)
Inventor
Schm�dt Walter
Birnstiel Max
Schweighoffer Tamas
Steinlein Peter
Buschle Michael
Original Assignee
Boehringer Ingelheim International Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from DE19543649A external-priority patent/DE19543649C2/de
Priority claimed from DE19607044A external-priority patent/DE19607044A1/de
Application filed by Boehringer Ingelheim International Gmbh filed Critical Boehringer Ingelheim International Gmbh
Publication of TR199800912T2 publication Critical patent/TR199800912T2/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0693—Tumour cells; Cancer cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/515—Animal cells
    • A61K2039/5154—Antigen presenting cells [APCs], e.g. dendritic cells or macrophages
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55516—Proteins; Peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cell Biology (AREA)
  • Biophysics (AREA)
  • Biotechnology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pulmonology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
TR1998/00912T 1995-11-23 1996-11-21 T�m�r a��s� ve a��n�n haz�rlanmas� i�in usul. TR199800912T2 (xx)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19543649A DE19543649C2 (de) 1995-11-23 1995-11-23 Tumorvakzine und Verfahren zu ihrer Herstellung
DE19607044A DE19607044A1 (de) 1996-02-24 1996-02-24 Tumorvakzine und Verfahren zu ihrer Herstellung

Publications (1)

Publication Number Publication Date
TR199800912T2 true TR199800912T2 (xx) 1998-08-21

Family

ID=26020603

Family Applications (1)

Application Number Title Priority Date Filing Date
TR1998/00912T TR199800912T2 (xx) 1995-11-23 1996-11-21 T�m�r a��s� ve a��n�n haz�rlanmas� i�in usul.

Country Status (24)

Country Link
US (1) US20020085997A1 (enExample)
EP (1) EP0866851A1 (enExample)
JP (1) JP2000502052A (enExample)
KR (1) KR19990067653A (enExample)
CN (1) CN1202931A (enExample)
AR (1) AR004341A1 (enExample)
AU (1) AU720131B2 (enExample)
BG (1) BG62999B1 (enExample)
BR (1) BR9611466A (enExample)
CA (1) CA2238176A1 (enExample)
CO (1) CO4520254A1 (enExample)
CZ (1) CZ158998A3 (enExample)
EE (1) EE03778B1 (enExample)
HU (1) HUP0000318A3 (enExample)
NO (1) NO982329D0 (enExample)
NZ (1) NZ322910A (enExample)
PL (1) PL188537B1 (enExample)
RO (1) RO115275B1 (enExample)
RU (1) RU2206329C2 (enExample)
SK (1) SK66998A3 (enExample)
TR (1) TR199800912T2 (enExample)
TW (1) TW514530B (enExample)
UY (2) UY24367A1 (enExample)
WO (1) WO1997019169A1 (enExample)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RS50101B (sr) 1996-02-24 2009-01-22 Boehringer Ingelheim International Gmbh., Farmaceutski preparati za imunomodulaciju
ATE389712T1 (de) 1997-01-31 2008-04-15 Edward P Cohen Krebs immuntherapie mit semi-allogenen zellen
ATE284707T1 (de) * 1997-08-22 2005-01-15 Science Park Raf S P A Tumorvakzinierung mittels verwendung autologer oder hla-verwandter antigen präsentierender zellen (apc), die mit einem tumorantigen sowie einem eine immunantwort hervorrufenden fremdantigen transduziert sind
US7014848B1 (en) 1998-03-20 2006-03-21 Genzyme Corporation Enhanced anti-tumor immunity
AU3102799A (en) * 1998-03-20 1999-10-11 Genzyme Corporation Enhanced anti-tumor immunity
FR2807661A1 (fr) * 2000-04-14 2001-10-19 Univ Nantes Agent et procede pour la simulation de lymphocytes t specifiques et lymphocytes t obtenus
EP1473564A4 (en) * 2001-09-18 2008-12-10 Greenpeptide Co Ltd METHOD FOR DETECTING CELL IMMUNITY AND ITS APPLICATION TO MEDICAMENTS
RU2203683C1 (ru) * 2001-09-20 2003-05-10 НИИ онкологии им. проф. Н.Н. Петрова Способ иммунотерапии костно-мозговыми дендритными клетками больных солидными опухолями
GB0209896D0 (en) 2002-04-30 2002-06-05 Molmed Spa Conjugate
CN1315536C (zh) * 2002-09-13 2007-05-16 李进 肿瘤抗原疫苗及其制备方法和疫苗组合物
GB0224442D0 (en) 2002-10-21 2002-11-27 Molmed Spa A delivery system
WO2005021029A2 (en) * 2003-08-25 2005-03-10 Agadjanyan Michael G Preventive cancer vaccine based on brother of regulator of imprinted sites molecule (boris)
RU2267326C2 (ru) * 2004-03-16 2006-01-10 ГУН НИИ онкологии им. проф. Н.Н. Петрова Минздрава РФ Способ иммунотерапии опухолевым лизатом с адъювантом беталейкин больных солидными опухолями
US7674456B2 (en) * 2004-06-14 2010-03-09 Charles Wiseman Breast cancer cell lines and uses thereof
CN103251946A (zh) * 2005-02-23 2013-08-21 健泰科生物技术公司 使用her二聚化抑制剂在癌症患者中延长病情进展前时间或存活
EP1871166A4 (en) 2005-03-29 2008-11-12 Univ Illinois CARCINOMAS AND THERAPEUTIC PROCEDURES
PL1760088T3 (pl) * 2005-09-05 2008-10-31 Immatics Biotechnologies Gmbh Związane z nowotworem peptydy wiążące się w sposób niedyskryminujący z cząsteczkami antygenu ludzkiego leukocytu klasy II (HLA)
US20090004213A1 (en) 2007-03-26 2009-01-01 Immatics Biotechnologies Gmbh Combination therapy using active immunotherapy
WO2011101465A1 (en) 2010-02-19 2011-08-25 Intercell Ag Ic31 nanoparticles
CN104662171B (zh) * 2012-07-12 2018-07-13 普瑟姆尼股份有限公司 个性化癌症疫苗和过继免疫细胞治疗
WO2017159686A1 (ja) 2016-03-15 2017-09-21 Ｒｅｐｅｒｔｏｉｒｅ Ｇｅｎｅｓｉｓ株式会社 免疫療法のためのモニタリングまたは診断ならびに治療剤の設計
CA3062591A1 (en) 2017-05-08 2018-11-15 Gritstone Oncology, Inc. Alphavirus neoantigen vectors
MX2021014525A (es) 2019-05-30 2022-03-17 Gritstone Bio Inc Adenovirus modificados.
CA3187258A1 (en) 2020-08-06 2022-02-10 Karin Jooss Multiepitope vaccine cassettes
CA3211645A1 (en) * 2021-03-12 2022-09-15 Erika VON EUW Methods of enhancing diversity of hla haplotype expression in tumors to broaden tumor cell susceptibility to tcr-t therapy

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6235525B1 (en) * 1991-05-23 2001-05-22 Ludwig Institute For Cancer Research Isolated nucleic acid molecules coding for tumor rejection antigen precursor MAGE-3 and uses thereof
JPH05246889A (ja) * 1992-03-05 1993-09-24 Seitai Chiyousetsu Kenkyusho:Kk 制癌方法および制癌剤
EP0569678A3 (de) * 1992-03-13 1994-10-26 Yeda Res & Dev Mit MHC-Genen doppelt transfizierte Zellen als Impfstoffe zur Immunoprevention von Tumormetastasen.

Also Published As

Publication number Publication date
PL188537B1 (pl) 2005-02-28
NZ322910A (en) 2000-05-26
PL326756A1 (en) 1998-10-26
JP2000502052A (ja) 2000-02-22
BG62999B1 (bg) 2001-01-31
HUP0000318A3 (en) 2002-02-28
CA2238176A1 (en) 1997-05-29
KR19990067653A (ko) 1999-08-25
SK66998A3 (en) 1998-12-02
UY24367A1 (es) 2000-10-31
EP0866851A1 (de) 1998-09-30
CZ158998A3 (cs) 1999-06-16
UY24430A1 (es) 1997-07-01
NO982329D0 (no) 1998-05-22
EE03778B1 (et) 2002-06-17
CO4520254A1 (es) 1997-10-15
RU2206329C2 (ru) 2003-06-20
CN1202931A (zh) 1998-12-23
US20020085997A1 (en) 2002-07-04
AU7694796A (en) 1997-06-11
EE9800161A (et) 1998-12-15
BR9611466A (pt) 1999-05-18
HUP0000318A2 (hu) 2000-06-28
WO1997019169A1 (de) 1997-05-29
TW514530B (en) 2002-12-21
AU720131B2 (en) 2000-05-25
RO115275B1 (ro) 1999-12-30
BG102439A (en) 1999-01-29
AR004341A1 (es) 1998-11-04

Similar Documents

Publication Publication Date Title
TR199800912T2 (xx) T�m�r a��s� ve a��n�n haz�rlanmas� i�in usul.
DE3851153D1 (de) Genetische modifizierung von endothelialen zellen.
DE3854194D1 (de) Monoklonale antikörper gegen glykosyliertes albumin, hybride zellinien, die diese antikörper produzieren, sowie deren verwendung.
ATE175446T1 (de) Immunogene peptide, antikörper sowie deren verwendungen im zusammenhang mit der cd4- rezeptorbindung
TR199900666T2 (xx) �nsan paratormonu ile ilgili peptidlere kar�� antikor.
EP0336364A3 (en) Modified cellular substrates used as linkers for increased cell retention of diagnostic and therapeutic agents
ATE63748T1 (de) Enzymwiderstandsfaehige immunomodulatorische peptide.
ATE273386T1 (de) Menschliches cyclin e
NO891711L (no) Hiv env-kodet peptid som er istand til aa fremkalle hiv-inhiberende antistoffer i pattedyr.
EP0284587A3 (en) Synthetic peptide antigens for the detection of hiv-1 infection
FI940375A0 (fi) Peptidit, joilla on elimiä suojaavaa vaikutusta, menetelmä niiden valmistamiseksi ja niiden käyttö terapiassa
ES8403157A1 (es) Un metodo de preparar sustancias biologicamente activas que tienen actividad anti-tumoral.
EP0344006A3 (en) Peptides that block the binding of hiv-1 to th CD4 receptor protein
ES2058479T3 (es) Compuestos peptidicos.
TR200001486T2 (tr) Hiperkeratozlu deri hastalıklarının tedavisi için diol ve alfa-hidroksi asitten oluşan bir karışımın kullanılması
ATE202485T1 (de) Neue protein-polykation-konjugate
TR199800981T2 (xx) Azimutsal sevk birimlerine sahip olan r�mork�r.
ATE122894T1 (de) Verwendung und zusammensetzung zur verbesserung des ''targeting'' von antikörpern, antikörperteilen, sowie konjugate derselben.
PT88539A (pt) Stabilisierung von therapeutisch wirksamen proteinen in pharmazeutischen zubereitungen
Nelson et al. Successful tumour immunotherapy: possible role of antibodies to anti-inflammatory factors produced by neoplasms
EP1200476A4 (en) ANTITUMAN ANTIBODIES, PROTEINS AND ITS USE
DK107389A (da) Modificerede proteiner
DE69804674D1 (de) Liposomen mit mehrfach verzweigten peptidkonstruktionen zur verwendung gegen hiv
ATE293163T1 (de) Cyclin e spezifische konstrukte und komplexe
EP0136093A3 (en) Anti-cancer factors